Major depressive disorder affects roughly 8% of U.S. adults in a given year. Treatment typically starts with talk therapy, antidepressants like SSRIs and SNRIs, or both. Many people respond well, but about a third don't find adequate relief with standard medications, driving research into new mechanisms and faster-acting treatments.
What's actually going on in research
Trials are testing esketamine nasal spray for treatment-resistant depression, psychedelic-assisted therapy with psilocybin and MDMA, neuromodulation devices like transcranial magnetic stimulation, and drugs targeting the kappa opioid receptor and neuroinflammation. Digital therapeutics combining therapy apps with medication are also being studied, along with blood tests to match people with the antidepressant most likely to work for them.
Psychedelic-assisted therapy
Psilocybin paired with therapy sessions has shown rapid and sustained improvements in multiple trials. MDMA-assisted therapy for depression with trauma history is also in late-stage testing.
Rapid-acting treatments
Esketamine, approved in 2019, can reduce depression within hours rather than weeks. Researchers are now testing similar NMDA receptor drugs that might work as quickly without dissociative side effects.
Inflammation-targeting drugs
Drugs that reduce brain inflammation are being tested in people whose depression may have an immune component. Early trials suggest this approach might help a subset of patients who don't respond to standard antidepressants.
What to know before you search
Eligibility usually depends on depression severity, number of prior treatment attempts, absence of bipolar disorder or psychosis, and sometimes specific symptom patterns like anxiety or sleep problems.
What types of trials are currently open
- Medication trials — Testing new antidepressants with different mechanisms than SSRIs and SNRIs, often in people who haven't responded to at least two standard treatments.
- Psychedelic therapy trials — Studying psilocybin or MDMA combined with structured therapy sessions, typically lasting several hours with trained guides.
- Device trials — Testing magnetic or electrical stimulation devices applied to the head, usually in outpatient sessions over several weeks.
- Digital therapeutic trials — Evaluating therapy apps, online programs, and virtual reality treatments, often as add-ons to medication or traditional therapy.
- Biomarker studies — Collecting blood, imaging, or genetic data to identify which treatments work best for which people, aiming to reduce trial-and-error prescribing.
Recently added Major Depressive Disorder trials
Track your transition from hospital to outpatient mental health services
This study is testing a new approach to help people with first episode psychosis transition successfully from the hospital to outpatient mental health care. Many patients lose contact with services after they leave the hospital, which can lead to worse outcomes. The investigators have developed a Transition Care Team (TCT) that works with patients while they are in the hospital and continues to support them after discharge. The team provides therapy, case management, and coordination with community programs that offer ongoing care. The main goal of the study is to find out if this new program increases the number of patients who successfully begin outpatient treatment after hospitalization, compared to usual care. The investigators will also look at whether the program improves symptoms, functioning, and overall well-being.
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder
Trauma-related Major Depressive Disorder (MDD) is frequently associated with poor response to conventional antidepressants, persistent psychological distress, and alterations in gut-brain axis function. Existing assessment tools primarily diagnose depression or PTSD but provide limited guidance for integrated clinical management. This study aims to develop and validate the Trauma Anxiety Depression Emotion (TADE) management tool while simultaneously evaluating the effectiveness of psilocybin-assisted Structured Integrated Reframing Therapy (SIRT) in improving clinical and biological outcomes. This prospective, four-arm randomized controlled trial will compare conventional therapy, psilocybin therapy, SIRT, and psilocybin-assisted SIRT. Participants will undergo assessment using the newly developed TADE tool together with established psychometric scales including HAM-D, PCL-5, and GAD-7. Biological outcomes will include serum gut-brain axis and inflammatory biomarkers, including Short-Chain Fatty Acids (SCFAs), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Zonulin, Occludin, and Glial Cell Line-Derived Neurotrophic Factor (GDNF). Assessments will be performed at baseline, during treatment, and at 12-week follow-up. The study aims to determine whether combining psilocybin with SIRT provides superior clinical improvement and favorable biological changes compared with either intervention alone while establishing the validity and clinical utility of the TADE management tool.
Find Major Depressive Disorder trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.